PDE4 Inhibitor Crystal Form 2 for Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing forms of the compound of formula (I), such as Form A, do not adequately address the need for improved solubility, bioavailability, and reduced lung accumulation after repeated administration, which are crucial for effective therapeutic applications, particularly in respiratory diseases.
Innovation Solution
The development of Crystal Form 2 of the compound of formula (I), characterized by specific XRPD peaks, which is obtained by dissolving Crystal Form A in acetone, leading to enhanced solubility, bioavailability, and reduced lung accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Crystal Form A is used, then the compound can be manufactured, but solubility and bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing a new crystal form (Crystal Form 2) with different physical parameters compared to Crystal Form A. The new crystal form exhibits improved solubility and bioavailability through its distinct crystal structure, as evidenced by different XRPD patterns and dissolution profiles. This represents a change in the physical state parameters of the compound to achieve better therapeutic performance.
Solution Approach 2:
The patent utilizes phase transitions between different crystal forms of the compound. By transitioning from Crystal Form A to Crystal Form 2 through controlled crystallization processes, the invention achieves improved solubility and bioavailability. The different crystal phases have distinct properties that directly impact the compound's performance in therapeutic applications.
2Duration of action of moving object
If repeated administration is performed, then therapeutic effect is maintained, but lung accumulation increases
Solution Approach 1:
The patent applies parameter changes by using Crystal Form 2 instead of Crystal Form A, which fundamentally alters the dissolution and absorption characteristics of the compound. This parameter change in crystal structure leads to reduced lung accumulation while maintaining therapeutic efficacy over repeated administrations, as the new crystal form allows for better clearance dynamics.
Solution Approach 2:
The patent converts the potential harm of lung accumulation into a benefit by using Crystal Form 2, which has improved dissolution properties. The enhanced solubility and dissolution rate of Crystal Form 2 facilitate faster absorption and clearance, transforming what would be a harmful accumulation effect into a beneficial rapid elimination profile that maintains therapeutic levels without toxic buildup.
3Device complexity
If Crystal Form A is used, then the formulation is simple, but dissolution rate is slow
Solution Approach 1:
The patent applies parameter changes by transitioning from Crystal Form A to Crystal Form 2, which has inherently faster dissolution kinetics due to its crystal structure characteristics. This parameter change in the physical state of the compound directly improves the dissolution rate without requiring complex formulation modifications, maintaining simplicity while enhancing performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Crystal Form 2 demonstrates significantly improved solubility in Simulated Lung Fluid, reduced risk of lung accumulation, and potentially better in vivo bioavailability, making it more effective for therapeutic use in respiratory diseases.
Implementation Method 1
by dissolving the crystal form A of the compound of formula (I) in acetone
Data Source
AI summary
The present invention relates to the crystal Form 2 of the compound of formula (I), to the process for its isolation and to the pharmaceutical compositions thereof. The present invention also relates to the crystal Form 2 of the compound of formula (I) for use as a medicament and for the manufacture of a medicament for the prevention and/or treatment of an inflammatory respiratory or obstructive respiratory disease.